Niraparib

TESARO Inc (NASDAQ: TSRO) fell as much as 9.8 percent Friday on news that Johnson & Johnson (NYSE: JNJ) suspended the enrollment of their shared phase 2 niraparib trial for prostate cancer. A Johnson & Johnson spokesperson told Benzinga the temporary hold isn't related to safety, and...

TESARO Inc (NASDAQ: TSRO) shares opened 3.25 percent higher after being halted around 3:30 p.m. ET. The company announced FDA approval of niraparib and plans to initiate registration processes for expanded indications of metastatic ovarian, breast and lung cancers. As of yet, niraparib supports...

Shares of TESARO Inc (NASDAQ: TSRO) fell more than 10 percent Tuesday after AstraZeneca plc (ADR) (NYSE: AZN) presented better trial results for its ovarian cancer drug. In a related development, shares of Clovis Oncology Inc (NASDAQ: CLVS) gained more than 10 percent to set a new 52-week high of $...

The incidence of ovarian cancer is supposed to be sporadic, with just about 3 percent of cancers among women said to originate from the ovaries. However, it is considered more lethal than any other cancer of female reproductive system. Clovis' Slice Of Luck So when the FDA granted accelerated...

Wedbush Securities reiterated its Outperform rating and raised its price target on TESARO Inc (NASDAQ: TSRO) shares to $139 from $107 as it "sees the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market." Waltham,...

Citi now sees 16.3 percent upside in the shares of TESARO Inc (NASDAQ: TSRO) following its price target increase to $90 from $65, as it is "now more confident about Niraparib approval in ovarian cancer and reimbursement." The 16.3 percent upside is based on the stock's June 29 closing price of $77....